India, April 19 -- https://tehelka.com/media/2025/04/Gopal-Misra-Column-CDRI-Lucknow-3.jpg
A sudden rollback of federal funding for public health research has jolted the US pharma landscape. With governors in 23 US states questioning the rollback, India sees both a warning and an opportunity to recalibrate its biotechnology ambitions. by Gopal Misra
The pharma and bio-tech industry in the US, continuously reinvigorated by the highly qualified researchers, state-of-the art laboratories, registering a large number of new patents of medicines, vaccines and new treatment protocols every year, have recently mobilized against President Donald Trump's decision to impose sudden cut in federal budget for the ongoing researches in the crucial pharm...